Other

Dataset Information

0

Treatment of a metabolic liver disease by in vivo prime editing in mice


ABSTRACT: Prime editing is a highly versatile CRISPR-based genome editing technology with the potential to correct the vast majority of genetic defects1. However, correction of a disease phenotype in vivo in somatic tissues has not been achieved yet. Here, we establish proof-of-concept for in vivo prime editing, that resulted in rescue of a metabolic liver disease. We first develop a size-reduced prime editor (PE) lacking the RNaseH domain of the reverse transcriptase (SpCas9-PERnH), and a linker- and NLS-optimized intein-split PE construct (SpCas9-PE p.1153) for delivery by adeno-associated viruses (AAV). Systemic dual AAV-mediated delivery of this variant in neonatal mice enables installation of a transversion mutation at the Dnmt1 locus with 15% efficiency on average. Next, we targeted the disease-causing mutation in the phenylalanine hydroxylase (Pah)enu2 mouse model for phenylketonuria (PKU). Correction rates of 1.5% using the dual AAV approach could be increased to up to 14% by delivery of full-length SpCas9-PE via adenoviral vector 5 (AdV5), leading to full restoration of physiological blood phenylalanine (L-Phe) levels below 120 µmol/L. Our study demonstrates in vivo prime editing in the liver at two independent loci, emphasizing the potential of PEs for future therapeutic applications.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE174757 | GEO | 2021/12/29

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-06-09 | GSE205532 | GEO
| PRJNA532891 | ENA
2024-04-22 | GSE247589 | GEO
2016-07-29 | E-GEOD-84534 | biostudies-arrayexpress
2022-02-03 | GSE195977 | GEO
2024-06-12 | GSE248085 | GEO
2023-07-18 | GSE218463 | GEO
2023-07-18 | GSE220763 | GEO
2023-08-02 | GSE239852 | GEO
2023-07-18 | GSE220765 | GEO